▸ The full interactive deep dive — interactive price chart (updated weekly), scores, fair value, and the expert-claim panel: research.synthosresearch.com/TGTX

Theme: Genomics/biotech (multiple sclerosis drug Briumvi) Date: 2026-07-02

1. What It Is

TG Therapeutics is a commercial-stage biopharmaceutical company focused on B-cell diseases. Its flagship approved product is Briumvi (ublituximab), an anti-CD20 monoclonal antibody for relapsing forms of multiple sclerosis, launched commercially in 2023. The company also has legacy/discontinued pipeline assets (umbralisib, cosibelimab) not central to the current investment case.

2. The Exponential Thesis

This is a single-drug commercial ramp story, not a platform/S-curve technology thesis. Briumvi revenue went from essentially $0 pre-launch (2021: $6.7M, 2022: $2.8M — pre-commercial) to $233.7M (2023) → $329.0M (2024) → $616.3M (2025), i.e., the company crossed from clinical-stage to a real commercial franchise in three years. FMP's forward estimates project continued strong growth: $941M (2026E) → $1.23B (2027E) → $2.26B (2030E), consistent with a drug still early in its launch curve gaining share in the crowded anti-CD20 MS market (competing with Ocrevus, Kesimpta). The "acceleration" in the screen (+47%) reflects this launch-curve dynamic — genuine, but a single-product story is inherently more fragile than a platform thesis, and the growth will decelerate as the drug matures/saturates its addressable MS population.

3. Financial Health

  • Revenue: $616.3M (2025), up 87% YoY from $329.0M (2024), up from $233.7M (2023). Real, fast, product-driven growth.
  • Profitability: Turned solidly profitable — operating income $123.3M (2025) vs. $41.9M (2024) and $20.6M (2023); net income $447.2M (2025) — note Q3 2025 alone had a $390.9M net income quarter, suggesting a one-time item (e.g., tax benefit or legal settlement) is likely inflating full-year net income; operating income is the cleaner read on core profitability (26.7% op margin FY25, up from 8.9% FY24).
  • Balance sheet: Cash $79.1M + short-term investments $62.8M = ~$142M liquid; total debt $260.7M; equity $648.0M (up sharply from $222.4M in 2024, consistent with the large net income print). Current ratio 4.1x — healthy near-term liquidity.
  • Cash flow: Operating cash flow still negative (-$24.8M in 2025, improved from -$40.5M in 2024) despite GAAP profitability — a gap worth watching, though the trend is converging toward breakeven.

4. Competitive Position / Moat

Briumvi competes in a crowded, well-capitalized MS market against Roche's Ocrevus and Novartis's Kesimpta — both larger, entrenched competitors with bigger sales forces. TGTX's edge is a differentiated dosing profile (shorter infusion) but no structural moat beyond patent-protected exclusivity on ublituximab. This is a mid-cap commercial biotech competing against giants, not a category-definer.

5. Valuation

P/S ~7.0x, EV/EBITDA ~33.4x, trailing P/E ~9.6x (cheap-looking on a P/E basis, but inflated by the likely one-time net income item noted above — a cleaner normalized P/E would be meaningfully higher). PEG of 0.02 (per the screen) implies the market is barely pricing in the forward growth — but that PEG is almost certainly distorted by the unusual 2025 net income spike, not a genuine "cheap growth" signal. On a P/S basis at 7x against ~50%+ revenue growth, this is a reasonable-to-full multiple for a single-drug commercial biotech, not obviously cheap. Fair-value stance: roughly fair, with the PEG metric unreliable due to the net-income anomaly.

6. What the Panel Says

Zero KB hits for "TGTX" or "TG Therapeutics." The screen's displayed "conviction 12.1 (49 claims)" for TGTX is a shared bucket artifact — those 49 claims belong to the broader "biotech/genomics" category (covering unrelated names like Natera, NovoCure, Isomorphic Labs/Lilly, radiopharmaceuticals, autism therapeutics, etc.) and do not name TG Therapeutics, Briumvi, or ublituximab anywhere. This is a confirmed false KB match — there is no genuine panel view on this specific company.

7. Key Risks

  1. Single-product concentration: Nearly all revenue and value rest on Briumvi's continued share gains in a competitive MS market — no meaningful pipeline diversification.
  2. Net income quality: The 2025 net income figure appears inflated by a one-time item (Q3 net income of $390.9M against ~$160M quarterly revenue); normalized earnings and therefore the trailing P/E/PEG are likely much less favorable than headline numbers suggest.
  3. Competitive/reimbursement pressure: Ocrevus and Kesimpta have far larger commercial infrastructure and could compress Briumvi's pricing or share trajectory.

8. Verdict

WATCH. One-line thesis: Genuine, fast commercial ramp on Briumvi in MS, but it's a single-drug story competing against much larger rivals, and the screen's valuation signal (PEG 0.02) is likely an artifact of a one-time net income item rather than a real "cheap growth" setup. Valuation stance: Fair (not the "extremely cheap" the raw PEG implies once the net-income anomaly is discounted). Biggest risk: Single-product concentration risk in a competitive, better-capitalized MS drug class. DATA FLAG: (1) Zero genuine KB/panel coverage — the "conviction 12.1 (49 claims)" figure is a shared biotech/genomics bucket, not TGTX-specific commentary. (2) 2025 net income likely includes a one-time item (Q3 net income $390.9M vs. ~$160M quarterly revenue) that inflates the trailing P/E and PEG favorability.